Assay Systems: Testing of Antiviral Drugs in Cell Culture (In Vitro)

  • Hans J. Eggers
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 143)


Testing for virus-inhibitory activity of chemicals in cell culture has sometimes furnished important leads in the development of antiviral drugs. The shortcomings of this so-called in vitro testing are obvious: substances which lack an effect on the viral replication cycle but, e.g., enhance antibody formation, improve nonspecific resistance, strengthen the interferon systems will not be detected by this method. Likewise, although so far only rarely described, some compounds affecting the viral replication cycle might reveal their antiviral effects only in an animal model, since metabolic activities of the organism, absent in cell culture, are required to convert the drug into its effective form. Most of the time, however, the reverse is true, viz. more compounds do appear active in a cell culture system than will later be found useful in the organism (Buthala, 1965; Eggers, 1977b). I shall refer to this problem in a later section.


Antiviral Activity Antiviral Drug Cell Culture System Cell Sheet Antiviral Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aboud, M., and Hassan, Y., 1983, Accumulation and breakdown of RNA-deficient intracellular virus particles in interferon-treated NIH 3T3 cells chronically producing Moloney murine leukemia virus. J. Virol. 45:489–495.PubMedGoogle Scholar
  2. Bablanian, R., Eggers, H.J., and Tamm, I., 1965, Studies on the mechanism of poliovirus-induced cell damage. I. The relation between poliovirus-induced metabolic and morphological alterations in cultured cells. Virology 26:100–113.PubMedCrossRefGoogle Scholar
  3. Bauer, D.J., and Sadler, P.W., 1960, The structure-activity relationships of the antiviral chemotherapeutic activity of isatin β-thiosemicarbazone. Br. J. Pharmac. Chemother. 15:101–110.Google Scholar
  4. Bucknall, R.A., 1973, The continuing search for antiviral drugs Adv. Pharmacol. Chemotherapy 11:295–319.Google Scholar
  5. Buthala, D.A., 1965, Experience gained in screening for synthetic antiviral compounds. Ann. N.Y. Acad. Sci. 130:Art. 1, 17–23.Google Scholar
  6. Crowther, D., and Melnick, J.L., 1961, Studies of the inhibitory action of guanidine on poliovirus multiplication in cell cultures. Virology 15:65–74PubMedCrossRefGoogle Scholar
  7. Davies, W.L., Grunert, R.R., Haff, R.F., McGahen, J.W., Neumayer, E.M., Paulshock, M., Watts, J.C., Wood, T.R., Herrmann, E.C., and Hoffmann, C.E., 1964, Antiviral activity of 1-adamantanamine (amantadine). Science 144:862–863.PubMedCrossRefGoogle Scholar
  8. De Clercq, E., 1979, Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses Cancer Letters 8:9–22.PubMedCrossRefGoogle Scholar
  9. De Clercq, E., Descamps, J., Verhelst, G., Walker, R.T., Jones, A.S., Torrence, P.F., and Shugar, D., 1980, Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J. Inf. Dis. 141:563–574.CrossRefGoogle Scholar
  10. De Somer, P., and Prinzie, A., 1957, Poliomyelitis virus neutralizing antibodies determination by filter paper discs on solidified bottle cultures. Virology 4: 387–388.CrossRefGoogle Scholar
  11. Dulbecco, R., 1952, Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc. Natl. Acad. Sci. 38:747–752.PubMedCrossRefGoogle Scholar
  12. Eggers, H.J., 1977a, Selective inhibition of uncoating of echovirus 12 by rhodanine. Virology 78:241–252.PubMedCrossRefGoogle Scholar
  13. Eggers, H.J., 1977b, Specific antiviral substances: testing in experimental animals and in “in vitro” systems. In: International Symposium on Experimental Animals and “in vitro” Systems in Medical Microbiology. WHO Collaborating Centre for Collection and Evaluation of Data on Comparative Virology. Munich, pp. 277–282.Google Scholar
  14. Eggers, H.J., 1982, Benzimidazoles. Selective inhibitors of picornavirus replication in cell culture and in the organism. In: Chemotherapy of Viral Infections. P.E. Came, and L.A. Caliguiri (eds.) . Springer-Verlag Berlin, Heidelberg, New York, pp. 377–417.CrossRefGoogle Scholar
  15. Eggers, H.J., and Tamm, I., 1961, Spectrum and characteristics of the virus inhibitory action of 2-(α- hydroxybenzyl)-benzimidazole. J. Exp. Med. 113:657–682.PubMedCrossRefGoogle Scholar
  16. Eggers, H.J., and Tamm, I., 1962, On the mechanism of selective inhibition of enterovirus multiplication by 2-(α-hydroxybenzyl)-benzimidazole. Virology 18:426–438.CrossRefGoogle Scholar
  17. Finter, N.B., 1970, Methods for screening in vitro and in vivo for agents active against myxoviruses. Ann. N.Y. Acad. Sci. 173:Art. 1, 131–138.CrossRefGoogle Scholar
  18. Gallo, R.C., Smith, R.C., Whang-Peng, J., Ting, R.C., Yang, S.S., and Abrell, J.W., 1972, RNA tumor viruses, DNA polymerases, and oncogenesis: some selective effects of rifampicin derivatives. Medicine 51:159–168.PubMedCrossRefGoogle Scholar
  19. Griengl, H., Bodenteich, M., Hayden, W., Wanek, E., Streicher, W., Stütz, P., Bachmayer, H., Ghazzouli, I., and Rosenwirth, B., 1985, 5-(Haloalkyl)-2′-deoxyuridines: a novel type of potent antiviral nucleoside analogue. J.Med. Chem. 28:1679–1684.PubMedCrossRefGoogle Scholar
  20. Hartmann, H., Hunsmann, G., and Eckstein, F., 1987, Inhibition of HIV-induced cytopathogeni ci ty in vitro by 3r-azi do-2′,3′-dideoxyguanosine. Lancet 1:115–116.Google Scholar
  21. Herrmann, E.C.,Jr., 1961, The detection, assay and evaluation of antiviral drugs. Progr. Med. Virol. 3:158–192.Google Scholar
  22. Herrmann, E.C.,Jr., Gabliks, J., Engle, C., and Perlman, P.L., 1960, Agar diffusion method for detection and bioassay of antiviral antibiotics. roc. Soc. Exp. Biol. Med. 103:625–628.Google Scholar
  23. Loddo, B., Ferrari, W., Brotzu, G., and Spanedda, A., 1962, In vitro inhibition of infectivity of polio viruses by guanidine. Nature 193:97–98.PubMedCrossRefGoogle Scholar
  24. McCormick, J.B., King, I.J., Webb, P.A., Scribner, C.L., Craven, R.B., Johnson, K.M., Elliott, L.H., and Belmont-Williams, R., 1986, Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:20–26.PubMedCrossRefGoogle Scholar
  25. Meindl, P., Bodo, G., Palese, P., Schulman, J., and Tuppy, H., 1974, Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 58:457–463.PubMedCrossRefGoogle Scholar
  26. Miller, P.A., Lindsay, H.L., Cormier, M., Mayberry, B.R., and Trown, P.W., 1970, Rapid semi-automated procedures for assaying antiviral activity. Ann. N.Y. Acad. Sci. 173:Art. 1, 151–159.CrossRefGoogle Scholar
  27. Mitsuya, H., and Broder, S., 1986, Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/ LAV) by 2′,3′-di deoxynucl eosides. Proc. Natl. Acad. Sci. 83:1911–1915.PubMedCrossRefGoogle Scholar
  28. Palese, P., and Schulman, J.L., 1974, Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 59:490–498.PubMedCrossRefGoogle Scholar
  29. Pauwels, R., De Clercq, E., Desmyter, J., Balzarini, J., Goubau, P., Herdewijn, P., Vanderhaeghe, H., and Vandeputte, M., 1987, Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J. Virol. Meth. in press.Google Scholar
  30. Rada, B, Blaškovič, D., Šorm, F., and Škoda, J., 1960, The inhibitory effect of 6-azauracil riboside on the multiplication of vaccinia virus. Experientia 15:487–488.CrossRefGoogle Scholar
  31. Rightsel, W.A., Dice, J.R., McAlpine, R.J., Timm, E.A., McLean, I.W., Jr., Dixon, G.J., and Schabel, F.M., Jr., 1961, Antiviral effect of guanidine. Science 134:558–559.PubMedCrossRefGoogle Scholar
  32. Rightsel, W.A., Schultz, P., Muething, D., and McLean, I.W., Jr., 1956, Use of vinyl plastic containers in tissue cultures for virus assays. J. Immunol. 76:464–474.PubMedGoogle Scholar
  33. Rosenwirth, B., and Eggers, H.J., 1977, Echovirus 12-induced host cell shutoff is prevented by rhodanine. Nature 267:370–371.PubMedCrossRefGoogle Scholar
  34. Smith, R.A., and Canonico, P., 1984, Ribavirin. In: Anti­viral Drugs and Interferon: the Molecular Basis of their Activity, Y. Becker (ed.). Martinus Nijhoff Publishing, Boston, pp. 253–269.CrossRefGoogle Scholar
  35. Smith, Th.J., Kremer, M.J., Luo, M., Vriend, G., Arnold, E., Kamer, G., Rossmann, M.G., McKinlay, M.A., Diana, G.D., and Otto, M.J., 1986, The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 233:1286–1293.PubMedCrossRefGoogle Scholar
  36. Tamm, I., and Eggers, H.J., 1963, Unique susceptibility of enteroviruses to inhibition by 2-(03a1-hydroxybenzyl)-benzimidazole and derivatives. 2nd International Symposium of Chemotherapy, H.P. Kuemmerle, P. Preziosi, P. Rentchnick (eds.). S. Karger, Basel, New York, pp. 88–118.Google Scholar
  37. Tamm, I., Eggers, H.J., Bablanian, R., Wagner, A.F., and Folkers, K., 1969, Structural requirements of selective inhibition of enteroviruses by 2-(α-hydroxybenzyl)-benzimidazole and related compounds. Nature 223:785–788.PubMedCrossRefGoogle Scholar
  38. Wendler, I., Bienzle, U., and Hunsmann, G., 1987, Neutralizing antibodies and the course of HIV induced disease. AIDS Research and Human Retroviruses, in press.Google Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Hans J. Eggers
    • 1
  1. 1.Institut für VirologieUniversität zu KölnKöln 41Germany

Personalised recommendations